Purpose of this Study
In this study, people will be placed into one of two groups by chance. One group will receive the study medicine and the other group will receive a placebo, which has no active medicine. The study medicine is given one or two times through a small needle in the lower back into the area around the spinal cord. The medicine is designed to lower a protein that builds up in the brains of people with Alzheimer disease. Participants will stay in the research center for a few days during treatment so doctors can watch them closely. They will also need to have a study partner who can go with them to many of the study visits.
Who Can Participate?
Eligibility
The study is open to people age 50-85, with changes in memory that also have key markers for Alzheimer's Disease that can be identified during screening for the study.
Age Range
50-85
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
The purpose is to study a new investigational drug in patients with early Alzheimer's Disease for safety.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
DNA06 - A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients with Early Symptomatic Alzheimer?s Disease J4T-MC-OLAA
Principal Investigator
Shruti
Raja
Protocol Number
PRO00116407
NCT ID
NCT06297590
Phase
I
Enrollment Status
Open to Enrollment